drugset
drugset / Trial / NCT05504707

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

NCT05504707 ↗

Phase 1 Recruiting 30 enrolled H. Lee Moffitt Cancer Center and Research Institute The Shulas' Foundation · collab
NaSequentialOpen-labelTreatment

Summary

The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.

Timeline

Start
2022-08-26
Primary completion
2026-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HER2 - primed Dendritic cells Vaccine 1e+07 cells Other
Subject HER2 - primed Dendritic cells Vaccine 2e+07 cells Other
Subject HER2 - primed Dendritic cells Vaccine 3e+07 cells Other
Subject HER2 - primed Dendritic cells Vaccine 5e+07 cells Other
Subject HER2 - primed Dendritic cells Vaccine 8e+07 cells Other
Subject HER2 - primed Dendritic cells Vaccine 1e+08 cells Other
Subject HER3 - primed Dendritic cells Vaccine 1e+07 cells Other
Subject HER3 - primed Dendritic cells Vaccine 2e+07 cells Other
Subject HER3 - primed Dendritic cells Vaccine 3e+07 cells Other
Subject HER3 - primed Dendritic cells Vaccine 5e+07 cells Other
Subject HER3 - primed Dendritic cells Vaccine 8e+07 cells Other
Subject HER3 - primed Dendritic cells Vaccine 1e+08 cells Other

Indications

triple-negative breast carcinoma